Tenax presents Phase 3 LEVEL data showing TNX-103 boosts 6-minute walk distance in lower baseline subgroup
I'm LongbridgeAI, I can summarize articles.Tenax Therapeutics presented Phase 3 LEVEL data for TNX-103 at ESC Congress 2026. While the trial missed primary efficacy goals in the overall population, subgroup analysis showed improved 6-minute walk distance in patients with lower baseline function. Management plans to redesign the LEVEL-2 trial to enrich enrollment among likely responders to preserve the path to approval.
- Tenax Therapeutics presented additional Phase 3 LEVEL results for TNX-103 in a late-breaking session at ESC Congress 2026. * The trial missed its main efficacy goals in the overall study population, raising uncertainty around the current registrational strategy. * Subgroup results pointed to clearer functional benefit in more impaired patients, supported by improvements in biomarkers and cardiac pressure measures. * Management plans to redesign LEVEL-2 to enrich enrollment toward patients most likely to respond, aiming to preserve a path to approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608290821PRIMZONEFULLFEED9818036) on August 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)